GW Pharmaceuticals Plc - American Depositary Shares GWPH releases its next round of earnings this Tuesday, Nov. 27. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
Earnings and Revenue
Based on management's projections, GW Pharmaceuticals analysts modeled for a loss of $2.46 per share on sales of $5.48 million.
GW Pharmaceuticals reported a per-share loss of 18 cents when it published results during the same quarter last year. Sales in that period totaled $2.86 million. Revenue would be have grown 91.41 percent from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | -2.67 | -2.48 | -2.13 | -1.26 |
| EPS Actual | -1.26 | -3.12 | -2.44 | -0.18 |
Stock Performance
Over the last 52-week period, shares are down 1.84 percent. Given that these returns are generally negative, long-term shareholders are probably unhappy going into this earnings release. Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. Analysts have been rating GW Pharmaceuticals stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
GW Pharmaceuticals' Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: http://www.investorcalendar.com/event/41034
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
